MorphoSys Aktie 944497 / DE0006632003
12.22
CHF
0.18
CHF
1.53%
18:00:00
BRX
Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Orderbuch | Analysen | |||||
Historisch | Ausblick |
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 99.92 |
Armistice Capital LLC | 5.16 |
RP Management LLC (Investment Management) | 3.91 |
T. Rowe Price International Ltd. | 3.39 |
Adage Capital Management LP | 3.21 |
Artisan Partners LP | 2.95 |
Vanguard Health Care Fund | 2.66 |
Government Pension Fund - Global (The) | 2.53 |
Baillie Gifford & Co. | 2.44 |
T Rowe Price International Stock Fund | 2.22 |
Vanguard International Growth Fund | 1.94 |
Vanguard Total International Stock Index Fund | 1.34 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|
Personal am Ende des Jahres | 329 | 426 | 615 | 732 |
Umsatz pro Mitarbeiter in Mio. EUR | 0.23 | 0.17 | 0.53 | 0.25 |
Bilanz (in Mio. EUR) - Aktiva
2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|
Summe Umlaufvermögen | 389 | 304 | 1'207 | 1'133 |
Summe Anlagevermögen | 488 | 437 | 940 | 571 |
Summe Aktiva | 539 | 496 | 1'660 | 2'556 |
Bilanz (in Mio. EUR) - Passiva
2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 0 | 43 | 318 | 326 |
Summe Fremdkapital | 50 | 102 | 1'038 | 2'311 |
Summe Eigenkapital | 488 | 395 | 621 | 245 |
Summe Passiva | 539 | 496 | 1'660 | 2'556 |
Adresse
Semmelweisstrasse 7, 82152 Planegg | |
Telefon | +49 (89) 89927-0 |
Fax | +49 (89) 89927-222 |
URL | http://www.morphosys.de |
Management
Andrew Cheng
Member-Supervisory Board |
Ann Merchant
Vice President & Head-Global Supply Chain |
Barbara Krebs-Pohl
Chief Business Officer |
Charlotte Lohmann
Senior Vice President & General Counsel |
Daniel Palmacci
President-Lonzas Cell & Gene Division |
George S. Golumbeski
Deputy Chairman-Supervisory Board |
Günter Wellnhofer
Head-Facilities |
Jean-Paul Kress
CEO & Chairman-Management Board |
Julia Neugebauer
Head-Investor Relations |
Klaus de Wall
Head-Accounting & Tax |
Krisja Vermeylen
Member-Supervisory Board |
Marc Cluzel
Chairman-Supervisory Board |
Maria Castresana
Senior VP & Global Head-Human Resources |
Michael Brosnan
Member-Supervisory Board |
Ralf Ostendorp
Senior Vice President, Head-Protein Sciences & CMC |
Sharon Evelyn Curran
Member-Supervisory Board |
Sung H. Lee
Chief Financial Officer |
Tim Demuth
Chief Research & Development Officer |